Avis de sécurité sur les produits de santé

Pays

* Les informations sont disponibles en anglais seulement.

⇡ Canada

Santé Canada – Rappels et avis de sécurité

Autres ressources

• InfoVigilance sur les produits de santé
• Quoi de neuf – MedEffet Canada
• Bulletins de l’ISMP Canada
• Médicaments sécuritaires (en anglais seulement)
• Registre des médicaments et des produits de santé
• Signaler un effet secondaire
• Capsules Rx – Avis de Santé Canada (connection requise)

⇡ États-Unis

FDA – Drug Safety Podcast

Drug safety communications

⇡ France

⇡ Royaume-Uni

• Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations
  26 Sep 2022
  Prescribers and dispensers should use caution if switching patients between different long-acting formulations of methylphenidate (Concerta XL, Medikinet XL, Equasym XL, Ritalin LA, and generics) as different instructions fo…
• Rucaparib (Rubraca▼): withdrawal of third-line treatment indication
  26 Sep 2022
  The third-line treatment indication for rucaparib has been withdrawn following a review of the findings of the ARIEL-4 trial, which showed lower overall survival for rucaparib treatment versus standard chemotherapy in patien…
• COVID-19 vaccines and medicines: updates for September 2022
  26 Sep 2022
  Recent information relating to COVID-19 vaccines and medicines that has been published since the August 2022 issue of Drug Safety Update, up to 23 September 2022.
• Letters and medicine recalls sent to healthcare professionals in August 2022
  26 Sep 2022
  A summary of recent letters and notifications sent to healthcare professionals about medicines
• Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
  23 Aug 2022
  Use of a nebuliser purchased independently of medical advice for use in the home to deliver nebulised asthma rescue medications to children can mask a deterioration in the underlying disease and may increase the risk of pote…
• COVID-19 vaccines and medicines: updates for August 2022
  23 Aug 2022
  Recent information relating to COVID-19 vaccines and medicines that has been published since the July 2022 issue of Drug Safety Update, up to 19 August 2022.
• Letters and medicine recalls sent to healthcare professionals in July 2022
  23 Aug 2022
  A summary of recent letters and notifications sent to healthcare professionals about medicines, and a patient safety alert on mexiletine hydrochloride.
• Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure
  21 Jul 2022
  We have initiated a new safety review into topiramate as a result of an observational study reporting an increased risk of neurodevelopmental disabilities in children whose mothers took topiramate during pregnancy. Topir…
• COVID-19 vaccines and medicines: updates for July 2022
  21 Jul 2022
  Recent information relating to COVID-19 vaccines and medicines that has been published since the June 2022 issue of Drug Safety Update, up to 20 July 2022.
• Letters and medicine recalls sent to healthcare professionals in June 2022
  21 Jul 2022
  A summary of recent letters and notifications sent to healthcare professionals about medicines.

⇡ Australie

⇡ Nouvelle-Zélande

• 8 September 2022
  8 Sep 2022
  Myocarditis and pericarditis have been reported with Nuvaxovid (Novavax COVID-19 Vaccine)
• 5 September 2022
  5 Sep 2022
  Recall of KetoSens Test Strips – batch UJ03PBXNG
• 29 August 2022
  29 Aug 2022
  Update – Possible risk of vasculitis with vildagliptin products (Galvus, Galvumet)
• 25 August 2022
  29 Aug 2022
  Abnormal uterine bleeding and oral anticoagulants (blood thinners)
• 13 July 2022
  29 Aug 2022
  Medsafe is publishing a warning that the product Nhan Sam Tuyet Lien Truy Phong Hoan should not be consumed
• 30 June 2022
  30 Jun 2022
  Accuretic found to contain nitrosamines
• 7 June 2022
  7 Jun 2022
  Typographical error in Healgen Rapid COVID-19 Antigen Self-Test (RATs) patient instruction leaflet
• 8 April 2022
  8 Apr 2022
  Reminder: Miracle Mineral Solution has dangerous and potentially life-threatening side effects
• 22 February 2022
  24 Feb 2022
  Possible risk of vasculitis with vildagliptin products (Galvus, Galvumet)
• 20 February 2022
  20 Feb 2022
  Buccaline tablets: review of the benefits and risks under section 36 of the Medicines Act 1981

⇡ Malaisie